GB2053176A - Spherical particles of activated carbon suitable for use in a pharmaceutical composition - Google Patents
Spherical particles of activated carbon suitable for use in a pharmaceutical composition Download PDFInfo
- Publication number
- GB2053176A GB2053176A GB8020864A GB8020864A GB2053176A GB 2053176 A GB2053176 A GB 2053176A GB 8020864 A GB8020864 A GB 8020864A GB 8020864 A GB8020864 A GB 8020864A GB 2053176 A GB2053176 A GB 2053176A
- Authority
- GB
- United Kingdom
- Prior art keywords
- particles
- activated carbon
- spherical
- pore
- spherical particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/30—Active carbon
- C01B32/312—Preparation
- C01B32/318—Preparation characterised by the starting materials
- C01B32/33—Preparation characterised by the starting materials from distillation residues of coal or petroleum; from petroleum acid sludge
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/30—Active carbon
- C01B32/354—After-treatment
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/30—Active carbon
- C01B32/354—After-treatment
- C01B32/384—Granulation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
Abstract
Spherical particles of activated carbon which effectively adsorb noxious substances in the alimentary tract without causing constipation, which is usually associated with a significant intake of conventional activated carbon particles, have a degree of sphericity such that the ratio of the maximum: minimum diameter of an individual said particle is in the range of 1.0 : 1 to 1.3 : 1 and at least 85% by weight of said particles are substantially truly spherical, the particles being smooth-surfaced, having a size of from 0.05 to 2 mm, a specific surface area of from 500 to 2,000 m<2>/g, and a pore-volume, in relation to pores having a pore-radius of from 100 to 75,000 ANGSTROM , of from 0.05 to 1.0 ml/g, and having been treated with ammonia such that their pH is from 6 to 8. The particles can be administered in the form of a phamaceutical composition to treat various intestinal disorders where toxins are produced in the alimentary tract.
Description
SPECIFICATION
Spherical particles of activated carbon suitable for use in a pharmaceutical composition
This invention relates to activated carbon particles to particles, to pharmaceutical compositions containing them, and to their production.
It has long been known that ingestion of activated carbon is effective as a treatment for diseases of the intestines, and activated carbon has been utilized for this purpose. It has been reported that the internal administration of activated carbon is particularly effective in treating various bacterial infectious diseases, such as dysentery, cholera and typhoid, and alimentary intoxications and digestive disorders, abdominal dropsy, chronic gastritis, epilepsy, dizziness, chlorosis and antrax. Also, a detoxifying effect has been obtained by the internal administration of activated carbon in the case of the ingestion a poison or an overdose of a medicine. Furthermore, the internal administration of activated carbon is effective for absorbing endogenous noxious substances in digestive organs, which are formed as a result of metabolic abnormalities accompanying various other diseases.
The effectiveness of activated carbon is attributed to the adsorption by the activated carbon of toxins in the digestive system, of abnormal metabolites or of substances which produce toxin(s) or cause the metabolic abnormalities. The particles of activated carbon which are employed are non-toxic to living bodies. The activated carbon together with the absorbed substances are excreted.
Hitherto, activated carbon has been used as indicated above in the form of a fine powder material, and it was orally administered with water or was taken after formulating to tablets. The activated carbon ingested as tablets is disintegrated to a fine powdery state in the digestive tracts and then exhibits its adsorbency as in the case of ingesting powdery activated carbon with water. However, the ingestion of powdery activated carbon or its tablets causes constipation as a side effect resulting to be a large demerit on the use of activated carbon as an antidote.Particularly, since activated carbon is administered in the cases of various diseases, the patient's physical strength has been consumed in most cases and accordingly, the constipation occurring as the side effect of administration of activated carbon not only gives a conspicuous pain to the patient but also may cause a fatal situation unless the constipation is resolved by mechanical means when the patient has no sufficient power of excretion. Accordingly, the provision of activated carbon which exhibits high detoxicating ability without causing constipation after its ingestion has been strongly desired.
In consideration of the above-mentioned situation, the inventor of the present invention has found that the specified spherical particles of activated carbon at least 85% by weight of which consists of truly spherical particles are suitable for use as an antidote or antidotal composition, which does not cause constipation after being orally administered. The above-mentioned spherical particles of antivated carbon have a ratio of the largest span to the smallest span of each particle of 1.0 to 1.3, a mean diameter of 0.05 to 2.0 mm, a specific surface area of 500 to 2,000 m2/g and a pore-volume of 0.5 to 1.0 ml/g of pores having a pore-radius of 100 to 75,000 , and at least 85% by weight of the particles is truly spherical.
Although the spherical particles of activated carbon characterized by the above-mentioned specific properties are suitable as an antidote without accompanying constipation, the inventor's study for further improvement was still continued. During the course of such a study, the inventor of the present invention has found that the treatment of said particles of activated carbon with ammonia surprisingly resulted in the reduction of the pH of said particles of activated carbon accompanied by the further improvement of the properties of said particles of activated carbon including their selective adsorbency.
The present invention concerns the spherical particles of activated carbon excellent in selective adsorbency to exogenous and endogenous noxious substances within the living body without causing constipation after being orally administered, thus extremely suitable for use as an antidote or antidotal composition which removes the above-mentioned noxious substances from the digestive system to detoxify such substances, and a method for preparing the above-mentioned spherical particles of activated carbon.
The followings are the more detailed explanation of the present invention: The spherical particles of activated carbon suitable for the antidote or antidotal composition according to the present invention are characterized by the following specified properties:
(1) comprising spherical particles and at least 85% by weight of the particles are truly spherical.
(2) the ratio of the largest span of each particle to the smallest span of the particle is in a range of 1.0 to 1.3; the diameter is in the range of 0.05 to 2.00 mm; the specific surface area is in a range of 500 to 2,000 m2/g and the pore-volume of pores of 100 to 75,000 A in pore-radius is in the range of 0.5 to 1.0 ml/g, and
(3) the pH of the particles of activated carbon is in the range of 6 to 8 attributable to the ammonia treatment.
As is stated above, the ratio of the largest span to the smallest span of each particle of the spherical particles of activated carbon according to the present invention is in a range of 1.0 to 1.3 and the particles are substantially truly spherical with its diameter of 0.05 to 2.0 mm without any conspicuous sharp unevenness and with smooth convex surface. In the case where the particle diameter is less than 0.05 mm, its side effect of causing constipation is inevitable in spite of its adsorbency, and on the other hand, in the case where its diameter is larger than 2.0 mm, it is not only difficult to be administered orally but also its antidotal efficacy is not exhibited rapidly after ingestion.
That is, the morphological specificity of particles of activated carbon is one of the important factors of antidotal function within the living body. In addition to the morphological speclticity, the specific surface area and the pore-volume of particles of activated carbon affectthe antidotal activity of the particles of activated carbon and the occurrence of constipation. in other words, in the case where the specific surface area and the pore-volume are too small, the adsorbency of the activated carbon is so small that the sufficient antidotal efficacy could not be obtained, and on the other hand, in the case where the above-mentioned two factors are too large, a phenomenon of constipation accompanies the oral administration in spite of not reducing the adsorbency of the activated carbon.The phenomenon is attributed to the collapse and disintegration of the particles of activated carbon into powders after ingestion due to the reduction of mechanical strength resulting from the too large specific surface area and the too large pore-volume.
The range of the specific surface area and the pore-volume of the particles of activated carbon according to the present invention have been decided from the consideration of the above-mentioned function of the particles of activated carbon within the living body, and the more preferable range of the specific surface area is 700 to 1,500 m2/g and the more preferable range of the pore-volume is 0.1 to 0.8 mi/g in the region of pore-radius of 100 to 75,000 .
The above-mentioned specific surface area and the pore-volume have been determined, respectively by an usual apparatus for determination of surface area and a mercury porosimeter.
Still more, the pH of the spherical particle of activated carbon according to the present invention is 6 to 8, said range of pH being attained by bringing ammonia into contact with the spherical particles of activated carbon of pH of higher than 8, and the pH value of 6 to 8 attributed to the ammonia treatment may be said specific.
The spherical particles of activated carbon of the present invention of pH of 6 to 8 show a selective adsorbing function on exogeneous and endogenous noxious substances. In other words, the spherical particles of activated carbon of pH of 6 to 8 according to the present invention exhibit within the living body an improved adsorbency on the above-mentioned noxious substances as compared with conventional powdery activated carbon ar merely spherically formulated or granulated activated carbon from powdery activated carbon.
It could not have been presumed that the spherical particles of activated carbon showing alkalinity are converted into those showing neutrality by bringing the former into contact with an alkaline reagent, i.e., an aqueous ammonia solution, and shows the above-mentioned change of their pH. Therefore, the surface state of the spherical particles of activated carbon treated with ammonia should be quite different from that of activated carbon of pH of 8 to 10. Hitherto, the adjustment of pH of activated carbon has been done by the usual means of neutralization by action of acids such as hydrochloric acid, sulfuric acid in case of basic activated carbons or by action of akalies such as sodium hydroxide, potassium hydroxide in case of acidic activated carbons.However, it is usually very difficult to adjust pH of activated carbon by the conventional method, in addition, undesirable contamination due to acidic or alkaline moiety such as chlorine, sulfuric sodium and potassium ions occurs in the resultant activated carbon in the conventional method.
Accordingly, the above-mentioned selective adsorbency of the spherical particles of activated carbon of the present invention may be considered to be attributed to the specific state of the surface of said spherical particles of pH of 6 to 8 obtained by the ammonia treatment.
The followings are the explanation of the method for producing the spherical particles of activated carbon according to the present invention:
The method of producing the spherical particles of activated carbon according to the present invention comprises the two steps in one of which the starting material is formulated into minute spherical particles and the thus formulated minute particles are activated to be minute spherical particles of activated carbon and in the other of which the minute spherical particles of activated carbon is treated with ammonia to adjust the pH of the particle to be 6 to 8.
As the above-mentioned starting material, a publicly known raw material for producing activated carbon such as saw-dust, coal, coconut-shell, pitches and synthetic organic high polymeric substances may be used.
In the first step of production, in cases where sawdust, coal and coconut-shell, etc. are used as the raw material, the pulverized material is formulated into minute spherical particles by the use of a binder, for instance, pitch, and then the particles are subjected to the carbonization and the carbonized particles are activated by heating at a temperature of 900 to 1 ,000 C in an atmosphere of water vapor, or in cases of using a pitch as the raw material, the pitch is formulated into minute spherical particles in a melt state according to the method disclosed in Japanese Patent Publication No. 50-18879 and the minute spherical particles are carbonized by the above-mentioned procedures after infusibilized by oxidation, and then activated to be minute spherical particles of activated carbon of a diameter of 0.05 to 2.0 mm, a pore-volume of 0.05 to 1.0 ml/g of pores having a pore-radius of 100 to 75,000 A and a pH of 8 to 10.
In the second step of production, the thus obtained spherical particles of activated carbon were brought into contact with an aqueous ammonia solution containing 1 to 1,000, preferably 5 to 100 ppm of NH3 and then.dried to be minute spherical particles of activated carbon of the same diameter, specific surface area, pore-volume as those of the particles of activated carbon before the ammonia-treatment, however, of pH of 6 to8.
By using a pitch as the raw material, the ratio of truly spherical particles in the thus obtained minute spherical particles of activated carbon is raised, and the surface of the particles become much more smooth with an improved mechanical strength. Accordingly, as the method for producing the activated carbon for use in the antidote or antidotal composition of the present invention, it is particularly preferable to adopt the latter method of production.
The above-mentioned second step of production is particularly important process of the production of the spherical particles of activated carbon of the present invention. Although the pH of conventional spherical particles of activated carbon is generally 8 to 10, the value of pH is converted to 6 to 8 in the second step and by such a process, the thus treated particles of activated carbon become to have an excellent property.
The condition of treatment with an aqueous ammonia solution in the above-mentioned second step depends on the state of spherical particles of activated carbon which have been subjected to activation by water vapour, however, usually the concentration of NH3 in the aqueous solution of ammonia is 1 to 1,000, preferably 5 to 100 ppm; the volume ratio of the aqueous ammonia solution to the spherical particles of activated carbon is 1 to 50, preferably 2 to 10 at a temperature of treatment of 10 to 50"C for a time period of treatment of 0.5 to 5 hours.
In cases where the concentration of NH3 in the aqueous ammonia solution is higher than the above-mentioned range, the pH of the product becomes alkaline and in cases where the concentration of
NH3 is lower than the above-mentioned range, the pH ofthe product remains still alkaline.
In the production, the thus treated spherical particles of activated carbon by the aqueous ammonia solution is usually dried at a temperature of 100 to 1 500C and then sifted to be a size suitable for internal administration. Since the sifting is carried out in order that the size of spherical particles of activated carbon is suitable for internal administration, that is, the uniformity of the size of each particle is improved and the ratio of the diameter of the largest particle to that of the smallest particle is made in the range of 1.0 to 3.0, the sifting may be carried out before the treatment with the aqueous ammonia solution.
The thus obtained spherical particles of activated carbon have the above-mentioned specific properties (1) to (3).
In the case where the spherical particles of activated carbon according to the present invention are applied as an antidote or antidotal composition, it is preferable to adopt the same method of ingestion as that for ingesting "charcoal for medical use". Although it is most convenient to ingest the above-mentioned spherical particles of activated carbon after dispersing into drinking water.
A pharmaceutical composition comprising the spherical particles of activated carbon and of a pharmaceutical carrier such as water-soluble or swellable high polymeric substances which dissolve or swell in water or aluminium hydroxide gel which releases the combined particles of activated carbon into free original spherical particulate state after ingestion and showing a form of, for instance, tablets, granules and capsules is possibly administered internally.
As for said high polymeric substances which dissolve or swell in water, soluble starch, dextrin, gelatin, gluten, gum arabic, methylcellulose, ethylcellulose, carboxymethylcellulose or its salt, hydroxyethylcellulose, hydroxypropylmethylcel lu lose, crystalline cellulose, cecellulose, amylose, polyvinyl alcohol, polyvinyl acetate, polyethylene glycol, etc. is possibly used.
The weight ratio of the activated carbon to the above-mentioned pharmaceutical carrier in the above-mentioned composition is in a range of 100 : 0 to 50: 50.
The dose level of the spherical particles of activated carbon depends on the degree of disease, the necessity of urgent detoxication, etc., however, usually 0.5 to 10 9/60 kg of body weight at a time, and three times per day. Although it is preferable to ingest between meals, the ingestion be excepted from the rule in urgent cases.
It has never been expected that the essentially spherical particles of activated carbon specified as above do not cause any constipation when administered while still exhibiting the antidotal efficacy. Although its reason has not been elucidated, this is presumably because the spherical particles of activated carbon of the present invention, retain their adsorbency of exogenous and endogenous toxins even in the presence of substances such as ingested foods, digested foods, feces and bile acids better as compared with conventional powdery activated carbon or simply formulated particles or granules from powdery activated carbon.
Still presumably because the conventional powdery activated carbon or formulated particles or granules of activated carbon which collapse into original powdery carbon in the juices of the alimentary canel tends to adsorb the stimulants for the intestines to weaken the entero-cinesia and at the same time is well mixed with feces, resulting in an increase of cohesion of the feces to cause constipation, on the other hand, the spherical particles of activated carbon according to the present invention does not serve to increase the cohesion and adsorbs the stimulants for the intestines in less amount, coupled with an advantage that the spherical particles of the present invention give a proper stimulation to the intestines, thus not causing constipation.
The above-mentioned merits of the spherical particles of activated carbon of the present invention are due to smoothness and physico-chemical state of the surface of said spherical particles.
The present invention is explained more in detail while referring to Examples as follows, however, it should be understood that the scope of the present invention is not restricted to these Examples.
EXAMPLE 1: {Production of the spherical particles of activated carbon).
In a stainless-steel autoclave provided with a stirrer, 750 parts by weight of a pitch (with a softening point of 175cm and an atomic ratio of H/C of 0.63) obtained by high-temperature cracking of crude petroleum oil and 250 parts by weight of naphthalene were introduced and after mixing and dissolving the pitch into naphthalene by heating to a temperature of 1700C, 3,000 parts by weight of an aqueous 0.5% by weight solution of "GOSENOL GH-170" (a polyvinyl alcohol-derived suspension agent, manufactured by Nippon
Gosei Company, Japan) were admixed with the solution under agitation. After continued and vigorous agitation for 60 minutes at a temperature of 130"C, the content of the autoclave was cooled to room temperature to form spherical particles rich in truly spherical particles.After removing the larger part of water, the remaining particles were immersed into 5 times by weight of methanol and the mixture was shaken to extract naphthalene into methanol. After removing naphthalene, the particles were dried by air flow and then they were heated in a small rotary kiln to a temperature of 300"C at a rate of 25 C/hour while blowing air into the kiln to obtain infusibilized particles. Then, the introduction of air into the kiln was stopped and while introducing water vapour into the kiln the particles were carbonized by raising the temperature of the kiln to 900"C and successively activated by maintaining the temperature at 900"C to obtain the spherical particles of activated carbon of 0.1 to 1.5 mm in diameter containing truly spherical particles in a high extent.Then, the ratio of the diameter of the largest particle to that of the smallest particle was adjusted to 1 to 3 by sifting.
A part of the thus adjusted particles of activated carbon was immersed into an aqueous ammonia solution containing 10 ppm of NH3 at the ratio of volume of the aqueous ammonia solution to weight of the particles of activated carbon of 10 ml/g for 3 hours at room temperature Then, the particles of activated carbon were separated from the aqueous solution and dried for 16 hours at a temperature of 110"C to obtain the spherical particles of activated carbon.
The characteristic properties of the thus obtained spherical particles of activated carbon are shown in
Table 1, those of the particles of activated carbon not yet treated with ammonia and powdery charcoal are also shown in Table 1 for comparison as Comparative specimens. In Table 1, the adsorbencies of both spherical particles of activated carbon to creatinine, respectively are illustrated, creatinine being known as a noxious substance which accomulates in the living body in metabolic abnormality caused by renal diseases.
TABLE 1
Specific properties of spherical particles of activated carbon
Characteristic Specimen 1 of Comparative Comparative
properties the present specimen 2 specimen 3
invention (4) (5) Diametver (mm) 0.26 to 0.6 0.25 to 0.6 < 0.06
Specific surface area (m2;g) 1,500 1,500 950
Pore-volume(ml g)(l) 0.35 0.35 1.8
Ratio of number of
substantially truly 98 98 < 5
spherical particles (%)
Adsorbency (mg 9)(2)
to creatinine 63 52 45 pH(3) 7.2 8.9 5.8
Notes: (1) Pore-volume of pores having radius of 100 to 75,000 A, determined by "Porosimetro Model 70"
made by Carlo Erba.
(2) Adsorbency was determined in an phosphate buffer solution containing each substrate at a
concentration of 5 mg dl at pH of 7.4.
(3) pH of the specimen was determined by the method described in Pharmacopoeia Japonica IX
Ed. for "charcoal for pharmacological use", that is:
After immersing 3 g of the specimen in 60 ml of distilled water and keeping for 5 minutes in
boiling, an amount ofdistilled water was added to compensate the loss due to evaporation,
and the pH of the liquid phase was determined after filtration. The value of the thus determined
pH of the liquid phase was taken as the pH of the specimen to be shown in Table 1.
(4) Spherical particles of activated carbon not treated with ammonia.
(5) Powdery charcoal.
The results of determination of the adsorbencies of the above-mentioned speciments of two kinds of spherical particles of activated carbon and of powdery charcoal to various digestive enzymes in vitro are shown in Table 2 for reference. In addition, the adsorbency of a commercial powdery charcoal to the same digestive enzymes are also shown in Table 2. The values in Table 2 are the determined values expressed by mg/g obtained by determination on each enzyme as a substrate at a concentration of 1 mg/dl in a phosphate buffer solution at pH of 7.4.
TABLE 2
Adsorbencies to digestive enzymes
Specimen 1 according Comparative Comparative
Enzyme to present invention specimen 2 specimen 3
Pepsin 8 12 85
Chymotrypsin 8 11 65
Amylase smaller than 1 smaller than 1 5
Lipase 5 7 35
It is seen from Table 2 that the adsorbency of the spherical particles of activated carbon (pH 7.2) according to the present invention is generally lower than those of spherical particles of activated carbon (pH 8.9) not yet treated with ammonia and of a commercial powdery charcoal to the digestive enzymes.
Acute toxicity of various activated carbons
Acute toxicity tests were carried out on mice using the specimens 1 and 2 shown in Table 1, and the results are shown in Table 3. As is seen in Table 3, it was recognized that the spherical particles of activated carbon according to the present invention were extremely safe even when administered in a large amount.
In these tests, each of the specimens of Table 1 was forcibly administered pesos to groups of commercial
ICR-JCL female mice of individual body weight of 22 e 1 g using a stomach tube, and after one week of the administration the mortality of the group of mice was observed. Although all the mice were autopsied after one week, no noticeable abnormal findings were observed on the external appearance or on internal organs without finding any noticeable symptons of intoxication.
TABLE 3
Results of acute toxicity tests
Route of Number of LD50
Specimen administra- mice in a
tion test group (g/kg)
Specimen 1
according to the peros 10 largerthan 15
present invention
Comparative
specimen 2 pesos 10 larger than 15
Note: Since the administration of more than 15 9, kg was extremely difficult, the test was discontinued at 15 gkg. There were no case of death.
EXAMPLE 2: (Function of the spherical particles of activated carbon within the living body):
An aqueous solution of pentobarbital sodium was orally administered to groups of female Wistar rats of individual body weight of 130 to 140 g at a dose rate of 20 mg of the medicine per kg body weight, and immediately after, an aqueous suspension of each specimen shown in Table 1 was orally administered at a dose rate of 200 mg/kg body weight. A group of the rats was kept as the control by administering only pentobarbital sodium. The number of rats in a group was 10. After pre-determined time periods, blood specimens were collected and the concentrations of pentobarbital sodium in the blood specimen were determined to find the mean value of the maximum concentration of the medicine in the blood.The percentage of the mean of maximum concentrations of the treated group to the mean of maximum concentrations of the control group is shown in Table 4 as the rate of removal of pentobarbital sodium from the rats.
As is seen in Table 4, the effect of removal of the medicine (referred to the effect of detoxication) was observed on every specimen of the spherical particles of activated carbon, however, the specimen 1 according to the present invention (treated by ammonia) showed a particularly remarkable detoxifying effect as compared to Comparative specimen 2 which has not been treated by ammonia.
TABLE 4:
Rate of removal of pentobarbital sodium by specimens
Specimen 1 according to Comparative Comparative
Specimen the present invention specimen 2 specimen3
Rate of removal 98.5 95.0 89.9
In the next place, after 90 minutes of the administration of each specimen of the spherical particles of activated carbon, ali the animals were sacrified by anesthesia and their digestive tracts were removed to observe the intestinal transfer of the administered particles of activated carbon. The ratio (percentage) of the distance from the cardia to the point at which the particles of activated carbon have arrived to the total length of the tract, from the cardia to the point at which the particles of activated carbon have arrived to the total length of the tract, from the cardia to the rectal end was recorded as the transfer rate, and the results of observation are shown in Table 5.As is seen in Table 5, in the group of rats to which the spherical particles of activated carbon according to the present invention were administered, the transfer rate is fairly larger than in the Comparative group, showing the less effect of causing constipation.
TABLE 5:
Intratestinal transfer rate of specimen
Specimen 1 according to Comparative Comparative
Specimen the present invention specimen 2 specimen 3
Transfer rate 75.5 72.0 52.1
EXAMPLE 3: (Adsorbency of the spherical particles ofactivated carbon):
In order to observe the adsorbency of the spherical particles of activated carbon according to the present invention, the following experiments were carried out in the presence of sodium stearate which is known to inhibit the adsorption of noxious substances by activated carbon in the intestines.
Into a phosphoric acid-buffer solution at pH of 7.4, sodium stearate was dispersed at a concentration of 2% by weight corresponding to the roughly estimated intestinal concentration of sodium stearate, and further, creatinine was dissolved into the solution at a concentration of 15 mg/dl.
Each of the specimen shown in Table 1 was added to the thus prepared solution and after 3 hour-shaking, the mixture was divided into portions of 5 ml.
After adding 3 drops of an aqueous 10% by weight aluminum sulfate solution to each aliquot of 5 ml to precipitate stearic acid, the concentration of creatinine in the supernatent layer of the aliquot was determined colorimetrically. The above-mentioned procedures were carried out at a temperature of 379C exceptforthe colorimetrical determination. From the values, the minimum concentration of creatinine on each series was obtained to culculate the adsorbed amount of creatinine onto the specimen. The results are shown in Table 6.
As is clearly seen in Table 6, the spherical particles of activated carbon according to the present invention is superior to Comparative specimen 2 (not treated with ammonia) and specimen 3 in adsorbency to creatinine. From the result, it is recognizable that the spherical particles of activated carbon according to the present invention, even in the presence of a substance such as sodium stearate which inhibits the adsorption of noxious substances such as creatinine by the activated carbon within the intestinal tracts, exhibits an excellent adsorbency to the noxious substances such as creatinine.
TABLE 6:
Adsorbency to creatinine in the process of sodium stearate
Specimen 1 according to Comparative Comparative
Specimen the present invention specimen 2 specimen 3
Amount of adsorbed
creatinine (1) 18.0 7.8 5.6
Note: (1) adsorbed amount of creatinine (mg) onto unit amount (g) of specimen of the particles of
activated carbon, and of specimen of the powdery charcoal.
Claims (19)
1. Activated carbon particles having a degree of sphericity such that the ratio of the maximum: minimum diameter of an individual said particle is in the range of 1.0 1 to 1.3:1 and at least 85% by weight of said particles are substantially truly spherical, the particles being smooth-surfaced, having a size of from 0.05 to 2mm, a specific surface area of from 500 to 2,000 m2/g and a pore-volume, in relation to pores having a pore-radius of from 100 to 75,000 , of from 0.05 to 1.0 ml/g and having been treated with ammonia such that their pH is from 6 to 8.
2. Particles according to claim 1, wherein at least 90% by number of said particles are substantially truly spherical.
3. Particles according to claim 1 or 2, wherein the size of said particles is from 0.1 to 1.0 mm.
4. Particles according to any one of the preceding claims, wherein the surface area of said particles is from 700 to 1,500 m2/g.
5. Particles according to any one of the preceding claims wherein the pore-volume of said particles, in relation to pores having a pore-radius of from 100 to 75,000 , is from 0.1 to 0.8 ml/g.
6. Activated carbon particles substantially as hereinbefore described with reference to Specimen 1 of
Example 1.
7. A pharmaceutical composition comprising, as active ingredient, activated carbon particles as claimed in any one of the preceding claims, together with a pharmaceutically acceptable carrier.
8. A composition according to claim 7 in a dosage unit form suitable for oral administration to a mammal to adsorb exogenous and/or endogenous toxins in the digestive tracts of said mammal and remove said toxins therefrom without causing constipation.
9. A process for preparing spherical activated carbon particles having a pH of from 6 to 8, which process comprises contacting spherical particles of activated carbon having a pH of higher than 8 with an aqueous ammonia solution.
10. A process according to claim 9 wherein the spherical particles of activated carbon have a degree of sphericity such that the ratio of the maximum : minimum diameter of an individual said particle is in range of 1.0 1 to 1.3 1 and at least 85% by weight of said particles are substantially truly spherical, the particles being smooth-surfaced and having a size of from 0.05 to 2 mm, a specific surface area of from 500 to 2,000 m2ig, and a pore-volume, in relation to pores having a pore-radius of from 100 to 75,000 , of from 0.05 to 1.0 ml/g.
11. A process according to claim 9 or 10 wherein at least 90% by number of the spherical particles of activated carbon are substantially truly spherical.
12. A process according to any one of claims 9 to 11 wherein the size of the spherical particles of activated carbon is from 0.1 to 1.0 mm.
13. A process according to any one of claims 9 to 12 wherein the surface area of the spherical particles of activated carbon is from 700 to 1,500 m2ig.
14. A process according to any one of claims 9 to 13 wherein the pore-volume of the spherical particles of activated carbon, in relation to pores having a pore-radius of from 100 to 75,000 , is from 0.1 to 0.8 ml/g.
15. A process according to any one of claims 9 to 14, wherein the concentration of ammonia in said aqueous ammonia solution is from 1 to 1,000 ppm.
16. A process according to any one of claims 9 to 15, wherein the spherical particles of activated carbon have been prepared from a pitch.
17. A process for the preparation of spherical activated carbon particles having a pH of from 6 to 8 substantially as hereinbefore described with reference to Specimen 1 of Example 1.
18. A pharmaceutical composition comprising, as active ingredient, spherical activated carbon particles which have been prepared by a process as claimed in any one of claims 9 to 17, together with a pharmaceutically acceptable carrier.
19. A composition according to claim 18 in a dosage unit form suitable for oral administration to a mammal to adsorb exogenous and or endogenous toxins in the digestive tracts of said mammal and remove said toxins therefrom without causing constipation.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8053779A JPS565313A (en) | 1979-06-26 | 1979-06-26 | Detoxificating spherical active carbon and preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB2053176A true GB2053176A (en) | 1981-02-04 |
| GB2053176B GB2053176B (en) | 1983-03-09 |
Family
ID=13721096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8020864A Expired GB2053176B (en) | 1979-06-26 | 1980-06-25 | Spherical particles of activated carbon suitable for use in a pharmaceutical composition |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS565313A (en) |
| CA (1) | CA1139673A (en) |
| DE (1) | DE3023848C2 (en) |
| FR (1) | FR2459660A1 (en) |
| GB (1) | GB2053176B (en) |
| IT (1) | IT1131386B (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2280898B (en) * | 1993-08-12 | 1997-07-16 | Bluecher Hasso Von | Activated carbon spherules and method of production thereof from ion-exchangers |
| US5807424A (en) * | 1994-06-17 | 1998-09-15 | Hasso von Blucher | Regenerative adsorption filter bed for exhauster hoods |
| DE19521666C2 (en) * | 1994-06-17 | 2002-02-14 | Bluecher Hasso Von | Sealing and frameless odor and / or pollutant filters |
| EP1249241A1 (en) * | 2001-04-11 | 2002-10-16 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| EP1407772A1 (en) * | 2002-10-09 | 2004-04-14 | Kureha Chemical Industry Co., Ltd. | Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases |
| EP1440692A1 (en) * | 2003-01-22 | 2004-07-28 | Futamura Kagaku Kogyo Kabushiki Kaisha | Medical adsorbent and process for production thereof |
| DE19513658B4 (en) * | 1994-04-19 | 2004-12-02 | Mhb Filtration Gmbh & Co. Kg | Odor filter for vacuum cleaners |
| US6830753B2 (en) | 2001-04-11 | 2004-12-14 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| EP1500397A1 (en) * | 2002-11-01 | 2005-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases |
| EP1525886A1 (en) * | 2003-10-22 | 2005-04-27 | Kureha Chemical Industry Co., Ltd. | Absorbent for oral administration, and agent for treating or preventing renal or liver disease |
| EP1547605A1 (en) * | 2002-11-01 | 2005-06-29 | Kureha Chemical Industry Co., Ltd. | Adsorbents for oral administration |
| WO2008021378A1 (en) * | 2006-08-17 | 2008-02-21 | Ocera Therapeutics, Inc. | Use of adsborbent carbon microspheres to treat intestinal bacterial infections |
| US7651974B2 (en) | 2002-11-01 | 2010-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| US8247072B2 (en) | 2006-02-14 | 2012-08-21 | Eastman Chemical Company | Resol beads, methods of making them and methods of using them |
| US8357366B2 (en) | 2004-04-02 | 2013-01-22 | Kureha Corporation | Adsorbent for an oral administration, and agent for treating or preventing renal or liver disease |
| US8440228B2 (en) | 2004-04-02 | 2013-05-14 | Kureha Corporation | Adsorbent for an oral administration, and agent for treating or preventing renal or liver disease |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3801457A1 (en) * | 1988-01-20 | 1989-08-03 | Hasso Von Bluecher | Activated carbon having high abrasion resistance and low moisture sensitivity |
| SU1706690A1 (en) * | 1988-04-19 | 1992-01-23 | Всесоюзный Научно-Исследовательский Институт Технического Углерода | Porous carbon material |
| DE3819000A1 (en) * | 1988-06-03 | 1989-12-14 | Hasso Von Bluecher | Bag of a teabag type for eliminating pollutants |
| JPH01309984A (en) * | 1988-06-08 | 1989-12-14 | Sanyo Electric Co Ltd | Method for preventing rusting of heat exchanger |
| JPH10316578A (en) * | 1997-05-13 | 1998-12-02 | Kureha Chem Ind Co Ltd | Medicine for improving blood lipoprotein lipase activity-lowering disease |
| JPH1129485A (en) * | 1997-07-10 | 1999-02-02 | Kureha Chem Ind Co Ltd | Antiobestic medicine |
| JP2003267715A (en) * | 2002-03-15 | 2003-09-25 | Osaka Gas Co Ltd | Activated carbon and its producing method |
| JP4311923B2 (en) * | 2002-10-07 | 2009-08-12 | 株式会社クレハ | Treatment or prevention agent for liver disease for oral administration |
| JP2005162683A (en) * | 2003-12-03 | 2005-06-23 | Kureha Chem Ind Co Ltd | Therapeutic or prophylactic agent for hyperuricemia |
| JP2005015482A (en) * | 2004-06-07 | 2005-01-20 | Koki Bussan Kk | Hazardous substance absorbing and removing agent |
| DE102005062160A1 (en) * | 2005-12-19 | 2007-06-21 | BLüCHER GMBH | Activated charcoal for medical use |
| JP5984352B2 (en) * | 2010-10-12 | 2016-09-06 | フタムラ化学株式会社 | Method for producing pharmaceutical adsorbent for oral administration |
| JP5985027B2 (en) * | 2010-10-12 | 2016-09-06 | フタムラ化学株式会社 | Method for producing pharmaceutical adsorbent for oral administration |
| ME02959B (en) | 2011-10-07 | 2018-07-20 | Teijin Pharma Ltd | Orally administered adsorbent containing activated carbon fiber |
| WO2018116947A1 (en) * | 2016-12-21 | 2018-06-28 | 株式会社クレハ | Spherical activated carbon and method for producing same |
| JP6637573B2 (en) * | 2017-12-18 | 2020-01-29 | フタムラ化学株式会社 | Adsorbent production method |
| WO2019131305A1 (en) * | 2017-12-28 | 2019-07-04 | 株式会社クラレ | Adsorption filter |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5018879A (en) * | 1973-06-20 | 1975-02-27 | ||
| US3917821A (en) * | 1973-10-23 | 1975-11-04 | Milton Manes | Palatable activated carbon |
| JPS53113193A (en) * | 1977-03-14 | 1978-10-03 | Asahi Chemical Ind | Activated charcoal for artificial viscera |
| JPS5489010A (en) * | 1977-12-27 | 1979-07-14 | Kureha Chem Ind Co Ltd | Spherical activated charcoal antidote |
-
1979
- 1979-06-26 JP JP8053779A patent/JPS565313A/en active Granted
-
1980
- 1980-06-19 CA CA000354378A patent/CA1139673A/en not_active Expired
- 1980-06-25 GB GB8020864A patent/GB2053176B/en not_active Expired
- 1980-06-25 FR FR8014129A patent/FR2459660A1/en active Granted
- 1980-06-25 DE DE3023848A patent/DE3023848C2/en not_active Expired
- 1980-06-26 IT IT23051/80A patent/IT1131386B/en active
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2280898B (en) * | 1993-08-12 | 1997-07-16 | Bluecher Hasso Von | Activated carbon spherules and method of production thereof from ion-exchangers |
| DE19513658B4 (en) * | 1994-04-19 | 2004-12-02 | Mhb Filtration Gmbh & Co. Kg | Odor filter for vacuum cleaners |
| US5807424A (en) * | 1994-06-17 | 1998-09-15 | Hasso von Blucher | Regenerative adsorption filter bed for exhauster hoods |
| DE19521666C2 (en) * | 1994-06-17 | 2002-02-14 | Bluecher Hasso Von | Sealing and frameless odor and / or pollutant filters |
| DE19521665C2 (en) * | 1994-06-17 | 2002-04-25 | Mhb Filtration Gmbh & Co Kg | Regenerable adsorption filter layer for extractor hoods |
| US6830753B2 (en) | 2001-04-11 | 2004-12-14 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| EP1249241A1 (en) * | 2001-04-11 | 2002-10-16 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| EP1407772A1 (en) * | 2002-10-09 | 2004-04-14 | Kureha Chemical Industry Co., Ltd. | Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases |
| US8309130B2 (en) | 2002-11-01 | 2012-11-13 | Kureha Corporation | Adsorbent for oral administration |
| EP1500397A4 (en) * | 2002-11-01 | 2005-03-30 | Kureha Chemical Ind Co Ltd | Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases |
| EP1547605A1 (en) * | 2002-11-01 | 2005-06-29 | Kureha Chemical Industry Co., Ltd. | Adsorbents for oral administration |
| EP1547605A4 (en) * | 2002-11-01 | 2005-11-02 | Kureha Chemical Ind Co Ltd | Adsorbents for oral administration |
| US7651974B2 (en) | 2002-11-01 | 2010-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| EP1500397A1 (en) * | 2002-11-01 | 2005-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases |
| EP1440692A1 (en) * | 2003-01-22 | 2004-07-28 | Futamura Kagaku Kogyo Kabushiki Kaisha | Medical adsorbent and process for production thereof |
| US7682442B2 (en) | 2003-01-22 | 2010-03-23 | Futamura Kagaku Kabushiki Kaisha | Medical adsorbent and process for production of the same |
| EP1525886A1 (en) * | 2003-10-22 | 2005-04-27 | Kureha Chemical Industry Co., Ltd. | Absorbent for oral administration, and agent for treating or preventing renal or liver disease |
| US8920796B2 (en) | 2003-10-22 | 2014-12-30 | Kureha Corporation | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| US8518447B2 (en) | 2004-04-02 | 2013-08-27 | Kureha Corporation | Method for treating or preventing renal or liver disease |
| US8357366B2 (en) | 2004-04-02 | 2013-01-22 | Kureha Corporation | Adsorbent for an oral administration, and agent for treating or preventing renal or liver disease |
| US8440228B2 (en) | 2004-04-02 | 2013-05-14 | Kureha Corporation | Adsorbent for an oral administration, and agent for treating or preventing renal or liver disease |
| US8865161B2 (en) | 2004-04-02 | 2014-10-21 | Kureha Corporation | Adsorbent for an oral administration, and agent for treating or preventing renal or liver disease |
| US8247072B2 (en) | 2006-02-14 | 2012-08-21 | Eastman Chemical Company | Resol beads, methods of making them and methods of using them |
| US8557381B2 (en) | 2006-02-14 | 2013-10-15 | Eastman Chemical Company | Resol beads, methods of making them, and methods of using them |
| WO2008021378A1 (en) * | 2006-08-17 | 2008-02-21 | Ocera Therapeutics, Inc. | Use of adsborbent carbon microspheres to treat intestinal bacterial infections |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS565313A (en) | 1981-01-20 |
| GB2053176B (en) | 1983-03-09 |
| FR2459660A1 (en) | 1981-01-16 |
| JPS6229368B2 (en) | 1987-06-25 |
| IT1131386B (en) | 1986-06-18 |
| CA1139673A (en) | 1983-01-18 |
| FR2459660B1 (en) | 1983-11-25 |
| DE3023848C2 (en) | 1985-10-24 |
| DE3023848A1 (en) | 1981-01-08 |
| IT8023051A0 (en) | 1980-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1139673A (en) | Spherical particles of activated carbon suitable for use as an antidotal pharmaceutical composition | |
| US4822765A (en) | Process for treating activated carbon with aqueous ammonia | |
| CA1112172A (en) | Antidote consisting of particles of activated carbon | |
| CA1149743A (en) | Porous and spherical carbonaceous product | |
| AU2009238282B2 (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
| KR100680448B1 (en) | Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases | |
| JP5124094B2 (en) | Pharmaceutical adsorbent | |
| KR100997504B1 (en) | Metal compounds, mixed or sulphated, as phosphate binders | |
| TWI507200B (en) | Pharmaceutical adsorbent and method for producing the same | |
| CA2150184C (en) | Pharmaceutical composition for the treatment of inflammatory bowel diseases | |
| EP0311244B1 (en) | Complex of magnesium oxide and titanium dioxide as a phosphate adsorbent | |
| JP3518878B2 (en) | Antinephrotic syndrome agent | |
| CA2150183C (en) | Pharmaceutical composition for the treatment of hemorrhoidal diseases | |
| KR100680449B1 (en) | Adsorbents for oral administration | |
| JPS6360009B2 (en) | ||
| JP4230005B2 (en) | Active vitamin D metabolism improver | |
| JPH0422618B2 (en) | ||
| JP5985027B2 (en) | Method for producing pharmaceutical adsorbent for oral administration | |
| KR840001449B1 (en) | A novel poroces and carbonaceous product | |
| US20170290856A1 (en) | Oral adsorbent and method for producing oral adsorbent | |
| RU2132697C1 (en) | Agent for prophylaxis of intestine tumor diseases | |
| WO2018227448A1 (en) | Orally-administered poison adsorbent and manufacturing method therefor | |
| CN1110136A (en) | Enteric solubility bacterial enzyme composite bed microcapsule preparation and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19970625 |